Evidence map›Paper›PMID 42676643›Full record

ArticleMilitary Medical Research2026

Yong-Jie Xu, Jian-Feng Xu, Chang-Fa Xia, Yu-Jie Wu, Dian-Ge Li, Tie-Yan Liu, Huai-Ping Cui, Jin Zhang, Liang Shang, Wan-Qing Chen

Abstract read
In one paragraph

Article in Military Medical Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yong-Jie XuOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jian-Feng XuBeijing Kangshu Medical Technology Co., Ltd., Beijing 100176, China.
Chang-Fa XiaOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yu-Jie WuOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Dian-Ge LiBeijing Kangshu Medical Technology Co., Ltd., Beijing 100176, China.
Tie-Yan LiuBeijing Kangshu Medical Technology Co., Ltd., Beijing 100176, China.
Huai-Ping CuiDepartment of Gastroenterological Surgery, Shandong Provincial Hospital of Shandong First Medical University, Jinan 250021, China.
Jin ZhangCixian Institute for Cancer Prevention and Control, Cixian Cancer Hospital, Handan 056500, Hebei, China.
Liang ShangDepartment of Gastroenterological Surgery, Shandong Provincial Hospital of Shandong First Medical University, Jinan 250021, China.
Wan-Qing ChenOffice of Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer remains a leading cause of cancer-related mortality worldwide, frequently diagnosed at advanced stages due to the limitations of current diagnostic approaches. While cell-free DNA (cfDNA)-based epigenetic profiling has emerged as a promising avenue for early cancer detection, comprehensive investigations into the epigenetic landscape of cfDNA in gastric cancer remain scarce. To address this gap, we aimed to develop and validate a multimodal epigenetic blood test for the non-invasive detection of gastric cancer. Methods: We developed Results: In cross-validation of the discovery dataset, Conclusions: The findings demonstrate that multimodal epigenetic analysis of cfDNA provides a robust, non-invasive strategy for early gastric cancer detection, with potential clinical utility to improve patient outcomes.

Indexed as

Cell-Free Nucleic AcidsEarly Detection of CancerStomach NeoplasmsAgedBiomarkers, TumorDNA MethylationEpigenesis, GeneticFemaleHumansMaleMiddle AgedROC CurveBiomarkers, TumorCell-Free Nucleic AcidsCell-free DNAEarly detectionEpigenetic biomarkersGastric cancer

Identifiers

PMID42676643
PMCPMC13527558

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.